ClinicalTrials.gg

Program

NVX-CoV2373 adjuvated lipid nanoparticle

Also written as “NVX-CoV2373”, “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)” and “NVX-Cov2373”.

Its studies are mostly in COVID-19 · Severe Acute Respiratory Syndrome, led by 4 companies.

Furthest: phase 4, since Oct 4, 202416 company-led studies, 1 open or runningNext primary completion: Nov 26, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novavax120 open or runningphase 4since Oct 4, 2024Apr 24, 2020none ahead
Takeda20 open or runningphase 3since Mar 27, 2022Jan 14, 2021none ahead
Cogna Technology Solutions10 open or runningphase 3since Feb 18, 2022Feb 18, 2022none ahead
Sanofi11 open or runningphase 4since Sep 30, 2026Sep 30, 2026Nov 26, 2026phase 4 · NCT07861542

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2020First study: phase 2 study in COVID-19New to NovavaxNovavax · NCT04368988 · 1,419 enrolled · United States, Australia
  2. Aug 28, 2020Phase 2 study in COVID-19Novavax · NCT04533399 · 4,422 enrolled · South Africa
  3. Oct 9, 20202 phase 3 studiesNovavax · NCT04583995, NCT04611802
  4. Jan 14, 2021Takeda’s first study: phase 2 study in Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)New to TakedaTakeda · NCT04712110 · 200 enrolled · Japan
  5. Oct 25, 2021Phase 2 study in COVID-19Novavax · NCT05112848 · 384 enrolled · South Africa
  6. Feb 18, 2022Cogna Technology Solutions’ first study: phase 3 study in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)New to Cogna Technology SolutionsCogna Technology Solutions · NCT05249816 · 1,000 enrolled · United Arab Emirates
  7. Mar 27, 2022Phase 3 study in COVID-19Takeda · NCT05299359 · 150 enrolled · Japan
  8. May 9, 2022Phase 3 study in COVID-19Novavax · NCT05372588 · 1,340 enrolled · Australia
  9. Jul 14, 20222 phase 3 studies in COVID-19Novavax · NCT05463068, NCT05468736
  10. May 16, 2023Phase 3 study in COVID-19Novavax · NCT05875701 · 147 enrolled · United States
  11. Jun 27, 2023Phase 3 study in COVID-19Novavax · NCT05925127 · 994 enrolled · United States
  12. Mar 1, 2024Phase 3 study in COVID-19Novavax · NCT06291857 · 9,320 enrolled · Australia, New Zealand
  13. Oct 4, 2024Phase 4 study in COVID-19Novavax · NCT06633835 · 660 enrolled · United States
  14. Sep 30, 2026Sanofi’s first study: phase 4 study in COVID-19New to SanofiSanofi · NCT07861542 · 669 enrolled · United States

Ahead

  1. Nov 26, 2026Primary completion: phase 4 study in COVID-19Sanofi · NCT07861542

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07861542COVID-19 · United States4Active, not recruitingSanofiNov 26, 2026669
NCT06633835COVID-19 · United States4CompletedNovavaxDec 30, 2024660
NCT06291857COVID-19 · Australia, New Zealand3CompletedNovavaxDec 24, 20259,320
NCT05925127COVID-19 · United States3CompletedNovavaxMay 21, 2024994
NCT05875701COVID-19 · United States3CompletedNovavaxNov 11, 2023147
NCT05468736COVID-19 · United States, Colombia, Dominican Republic and more3CompletedNovavaxJan 16, 20243,600
NCT05463068COVID-19 · United States3CompletedNovavaxAug 17, 2022911
NCT05372588COVID-19 · Australia3CompletedNovavaxJul 17, 20221,340
NCT05299359COVID-19 · Japan3CompletedTakedaJun 11, 2022150
NCT05249816Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · United Arab Emirates3CompletedCogna Technology SolutionsMay 4, 20231,000
NCT05112848COVID-19 · South Africa2CompletedNovavaxMay 23, 2022384
NCT04712110Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) · Japan2CompletedTakedaMar 28, 2022200
NCT04611802Severe Acute Respiratory Syndrome · United States, Mexico, Puerto Rico3CompletedNovavaxApr 10, 202333,000
NCT04583995COVID-19 · United Kingdom3CompletedNovavaxMar 29, 202215,185
NCT04533399COVID-19 · South Africa2CompletedNovavaxDec 7, 20214,422
NCT04368988COVID-19 · United States, Australia2CompletedNovavaxJun 1, 20221,419

How it is read

Names in the registry

  • “NVX-CoV2373”, 3 entries
  • “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)”, 2 entries
  • “NVX-Cov2373”, 2 entries
  • “TAK-019”, 2 entries
  • “Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
NVX-CoV2373 adjuvated lipid nanoparticle (Novavax): development program | ClinicalTrials.gg